PMID- 34049519
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210602
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 22
IP  - 1
DP  - 2021 May 28
TI  - Duloxetine reduces pain after Total hip arthroplasty: a prospective, randomized 
      controlled study.
PG  - 492
LID - 10.1186/s12891-021-04377-4 [doi]
LID - 492
AB  - BACKGROUND: Previous studies have demonstrated the efficacy of duloxetine in 
      reducing postoperative pain and opioid consumption. However, the effect of 
      duloxetine on total hip arthroplasty (THA) remains unclear. The objective of this 
      study was to assess the efficacy of oral duloxetine in THA. METHODS: We enrolled 
      96 patients in this randomized controlled trial. These patients were randomized 
      (1,1) to either the duloxetine group or the placebo group and received daily 
      doses of 60 mg duloxetine or placebo, respectively, from 2 d pre-operation to 14 
      d after surgery. The primary outcome was pain severity upon movement measured by 
      a visual analogue scale (VAS). The secondary outcomes included VAS scores for 
      resting pain, morphine consumption, Harris Hip Score, patient satisfaction at 
      discharge, length of postoperative hospital stay, and adverse events. RESULTS: 
      Patients in the duloxetine group had significantly lower pain severity scores 
      upon movement within 3 postoperative weeks (p < 0.05) while none of the 
      differences met the minimum clinically important difference (MCID). Moreover, 
      patients in the duloxetine group performed better in terms of resting pain (in 
      3 weeks after surgery), morphine requirements, and satisfaction level at 
      discharge (all p < 0.05). There was no difference between groups in the 
      prevalence of adverse events. CONCLUSIONS: Although it did not result in a 
      clinically meaning reduction in pain after total hip arthroplasty, perioperative 
      administration of 60 mg of duloxetine daily significantly alleviated pain in the 
      postoperative 3 weeks and morphine requirements during the postoperative 48 h. 
      Therefore, duloxetine still shows promise in optimizing the multimodal 
      pain-management protocols in total hip arthroplasty. TRIAL REGISTRATION: Chinese 
      Clinical Trial Registry, ChiCTR2000033606 , 06/06/2020.
FAU - Li, Hao
AU  - Li H
AD  - Department of Orthopaedics, West China Hospital, Sichuan University, 37# 
      WuhouGuoxue Road, Chengdu, China.
FAU - Zeng, Wei-Nan
AU  - Zeng WN
AD  - Department of Orthopaedics, West China Hospital, Sichuan University, 37# 
      WuhouGuoxue Road, Chengdu, China.
AD  - Department of Orthopaedics, Chongqing General Hospital, University of Chinese 
      Academy of Sciences, Chongqing, China.
FAU - Ding, Zi-Chuan
AU  - Ding ZC
AD  - Department of Orthopaedics, West China Hospital, Sichuan University, 37# 
      WuhouGuoxue Road, Chengdu, China.
FAU - Yuan, Ming-Cheng
AU  - Yuan MC
AD  - Department of Orthopaedics, West China Hospital, Sichuan University, 37# 
      WuhouGuoxue Road, Chengdu, China.
FAU - Cai, Yong-Rui
AU  - Cai YR
AD  - Department of Orthopaedics, West China Hospital, Sichuan University, 37# 
      WuhouGuoxue Road, Chengdu, China.
FAU - Zhou, Zong-Ke
AU  - Zhou ZK
AD  - Department of Orthopaedics, West China Hospital, Sichuan University, 37# 
      WuhouGuoxue Road, Chengdu, China. zhouzongke@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210528
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
RN  - 0 (Analgesics)
RN  - 9044SC542W (Duloxetine Hydrochloride)
SB  - IM
MH  - Analgesics/therapeutic use
MH  - *Arthroplasty, Replacement, Hip/adverse effects
MH  - Double-Blind Method
MH  - Duloxetine Hydrochloride/adverse effects
MH  - Humans
MH  - Prospective Studies
PMC - PMC8161627
OTO - NOTNLM
OT  - Duloxetine
OT  - Postoperative pain
OT  - Total hip arthroplasty
COIS- The authors declare that they have no competing interests.
EDAT- 2021/05/30 06:00
MHDA- 2021/06/02 06:00
PMCR- 2021/05/28
CRDT- 2021/05/29 05:26
PHST- 2021/02/18 00:00 [received]
PHST- 2021/05/18 00:00 [accepted]
PHST- 2021/05/29 05:26 [entrez]
PHST- 2021/05/30 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
PHST- 2021/05/28 00:00 [pmc-release]
AID - 10.1186/s12891-021-04377-4 [pii]
AID - 4377 [pii]
AID - 10.1186/s12891-021-04377-4 [doi]
PST - epublish
SO  - BMC Musculoskelet Disord. 2021 May 28;22(1):492. doi: 10.1186/s12891-021-04377-4.